Literature DB >> 33636644

A comprehensive study of the metabolism of flavonoid oroxin B in vivo and in vitro by UHPLC-Q-TOF-MS/MS.

Rui Feng1, Xiaowei Zhang2, Jintuo Yin3, Yuqian Zhang2, Yinling Ma4, Xia Zhang2, Lantong Zhang5, Deqiang Li6.   

Abstract

Oroxin B, a flavonoid, is a major bioactive component form Oroxylum indicum (L.) Vent. with enormous anti-hepatoma effects. To data, the oroxin B metabolism studies remain underexplored. This study was designed to characterize oroxin B metabolism in vivo and in vitro by ultrahigh-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UHPLC-Q-TOF-MS/MS). Consequently, 30 metabolites in rats, 8 metabolites in liver microsomes and 18 metabolites in intestinal bacteria were identified, and 9 metabolites were recognized by comparison with standards. The biotransformation processes involved ketone, acetylation, loss of C12H20O10, and loss of C6H10O5. And baicalein and oroxin A were generated after loss of C12H20O10, and loss of C6H10O5, respectively, and further went through some other reactions, such as oxidation, methylation, internal hydrolysis, hydrogenation, loss of O, ketone, glycine conjugation, glucuronide conjugation and their composite reactions. The results provide valuable evidence for elucidation the potential mechanism of oroxin B pharmacological action, and offer reasonable guidelines for further investigations of oroxin B safety and efficacy.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  In vivo and in vitro; Metabolism; Oroxin B; UHPLC-Q-TOF-MS/MS

Mesh:

Substances:

Year:  2021        PMID: 33636644     DOI: 10.1016/j.jpba.2021.113905

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  1 in total

1.  The development and validation of a sensitive HPLC-MS/MS method for the quantitative and pharmacokinetic study of the seven components of Buddleja lindleyana Fort.

Authors:  Xia Zhang; Zhi-Qing Zhang; Li-Cang Zhang; Ke-Xin Wang; Lan-Tong Zhang; De-Qiang Li
Journal:  RSC Adv       Date:  2021-07-28       Impact factor: 4.036

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.